Obecabtagene autoleucel consolidation for newly diagnosed high-risk B-cell acute lymphoblastic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional trial gives adults with newly diagnosed high‑risk B‑cell ALL a single infusion of anti‑CD19 autologous CAR‑T cells (obecabtagene autoleucel) as consolidation after they achieve first remission with standard chemoimmunotherapy. The primary endpoint is 18‑month event‑free survival (EFS), with secondary endpoints including 24‑month overall survival, rates of persistent MRD negativity by flow cytometry and NGS (and BCR::ABL1 PCR for Ph‑positive patients), and safety. Participants will be monitored for CAR‑T expansion and B‑cell aplasia with scheduled assays up to 12 months post infusion and longer follow‑up for survival and subsequent therapies. Manufacturing and central laboratory testing are performed in collaboration with the CAR‑T developer and certified labs, and the intervention and follow‑up occur at the trial site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

I. Patients of age .18 years with high-risk B-cell ALL in first remission and \<5% BM blasts with at least one high-risk feature defined as:

1. Ph-negative B-cell ALL:

   1. KMT2A rearranged ALL
   2. Complex cytogenetics as per NCCN 2022
   3. Low-hypodiploidy/tetraploidy
   4. Philadelphia-like ALL (based on CRLF2 overexpression or recurrent Ph-like genetic fusions)
   5. TP53 mutation (variant allele fraction \>2%)
   6. Persistent MRD by flow cytometry and/or NGS
2. Ph-positive B-cell ALL:

   1. IKZF1plus genotype (IKZF1 deletion coexisting with PAX5 or CDKN2A/2B, or PAR1 region deletions) or other high-risk features such as VPRB1 deletion, etc.
   2. High WBC (\>30 x 109/L) at initial presentation
   3. Persistent MRD by flow cytometry and/or NGS and/or PCR II. Performance status of 0, 1, or 2 III. Adequate organ function with creatinine less than or equal to 1.6 mg/dl, bilirubin less than or equal to 3.5 mg and ALT and AST less than or equal to 5 times institutional upper limit of normal IV. Patients should be CD19 expression positive (\>1%) before enrollment V. Patients with controlled CNS and/or other extramedullary leukemia will be eligible.

Exclusion Criteria:

1. Pregnant or lactating; women of child-bearing potential (WOCBP) must have negative pregnancy test. WOCBP defined as not post-menopausal for 12 months or no previous surgical sterilization.
2. Patients with history of Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) infections, even if under control. (Patients with Hepatitis B core antibody positive alone will not be an exclusion factor if HBV DNA PCR is negative).
3. Active and uncontrolled disease/infection as judged by the treating physician
4. Unable or unwilling to sign the consent form

Where it's running

• The University of Texas M. D. Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Elias Jabbour, MD — M.D. Anderson Cancer Center
• Study coordinator: Elias Jabbour, MD
• Email: ejabbour@mdanderson.org
• Phone: (713) 792-4764

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

• CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes

  This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.

  Recruiting Resonance, Inc. · Yerevan and 5 other locations · NCT07632014

• First-in-human testing of 4A10 for relapsed or hard-to-treat ALL and lymphoblastic lymphoma

  This early-stage trial tests a new antibody therapy called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma to see if it is safe and how the body handles it.

  Recruiting at 5 sites Phase 1 Allterum Therapeutics, Inc · Aurora, Colorado and 6 other locations · NCT07586618

• Plasma cell-free DNA in children with ALL to help monitor disease

  This study tests whether measuring tumor DNA in blood can help monitor acute lymphoblastic leukemia in kids without needing frequent bone-marrow tests.

  Recruiting at 2 sites Assistance Publique - Hôpitaux de Paris · Paris and 1 other locations · NCT07483476

• Laughter and fun yoga to ease chemotherapy pain in children

  This tests whether a home-based program of laughter and kid-friendly yoga can lower pain in children aged 2–10 who are receiving chemotherapy for acute lymphoblastic leukemia.

  Recruiting Beirut Arab University · Sidon · NCT07327138

• Tracking and predicting chemotherapy-related nerve damage in children with acute lymphoblastic leukemia

  Researchers will track how vincristine-related nerve damage develops over time in children (ages 8–17) with acute lymphoblastic leukemia and try to identify factors that predict different symptom patterns.

  Recruiting at 3 sites The Hong Kong Polytechnic University · Zhengzhou, Henan and 2 other locations · NCT07326930

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.